This is the authors' abstract. We don't add key points for this paper.
Background Covalent inhibition of disease-associated proteins offers a rapid and robust strategy for drug discovery. METTL16, an RNA N6-methyladenosine (m6A) methyltransferase, plays oncogenic roles in multiple cancers, yet its effective covalent inhibitors remain limited. Methods We employed a reverse activity-based protein profiling (reverse ABPP) using a library of natural products and clinically approved drugs to identify covalent binders of METTL16. Recombinant METTL16 and its MTase domain were used for in vitro labeling, competitive binding, and enzymatic inhibition assays. Binding sites were mapped via LC-MS/MS, and molecular dynamics simulations assessed the impact of covalent modification on RNA binding and methylation activity. We also evaluated changes in the METTL16 interactome upon treatment with gallic acid (GA). GA derivatives were analyzed to probe structure–activity relationships. Results GA was identified as a covalent inhibitor of METTL16, forming bonds with residues K252 and C253 within the RNA-binding groove. Molecular dynamics simulations indicated that such binding impairs substrate positioning and methylation activity. GA also disrupted METTL16’s interactions with translation machinery in cells. Structure–activity analysis revealed that the pyrogallol moiety is essential for covalent targeting, whereas carboxyl modifications had a limited impact. Indeed, epigallocatechin-3-gallate (EGCG), containing two pyrogallol groups, exhibited stronger inhibition and enhanced suppression of cancer cell proliferation compared to GA. Conclusions Reverse ABPP enabled rapid identification of METTL16 covalent inhibitors, highlighting pyrogallol as an effective reactive warhead. GA and EGCG serve as promising lead compounds. This strategy provides a framework for the development of targeted covalent inhibitors against METTL16 and other therapeutically important protein targets.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: